Monday, March 4, 2019

FDA will not include vasopressin on 503B bulks list

The Pharma Letter-14 hours ago
As a result, it will be unlawful for outsourcing facilities to sell compoundedvasopressin products unless they manufacture those products using an FDA-approved ..

No comments: